Both plasma TG levels and transaminase activity are significantly lower in AD patients harboring the APOE-4/4 genotype, probably indicating (i) that low TG levels protect against liver steatosis and (ii) that the presence of the APOE-4 allele influences TG levels, liver steatosis, and transaminase activity. This evidence concerns the gene APOE and fatty liver disease.